- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | Lixte Biotechnology Holdings, Inc.: LIXTE Launches New Study to Determine if Certain Pre-Cancerous Cells Found in an Aging Population Can Be Eliminated by LB-100 | 1 | GlobeNewswire (USA) | ||
| LIXTE BIOTECHNOLOGY Aktie jetzt für 0€ handeln | |||||
| 27.03. | LIXTE BIOTECHNOLOGY HOLDINGS, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 27.03. | Lixte Biotechnology Holdings, Inc.: LIXTE Biotechnology Provides Update On Progress with Proprietary Compound, LB-100, to Treat Ovarian and Colorectal Cancer | 80 | GlobeNewswire (Europe) | -Started Two New Clinical Trials, Collaborating with MD Anderson and The Netherlands Cancer Institute for Treatment of Ovarian and Colorectal Cancer- -Received Exclusive Patent License Agreement with... ► Artikel lesen | |
| 24.03. | LIXTE BIOTECHNOLOGY HOLDINGS, INC. - 10-K, Annual Report | 3 | SEC Filings | ||
| 11.03. | LIXTE BIOTECHNOLOGY HOLDINGS, INC. - 8-K, Current Report | 2 | SEC Filings | ||
| 25.02. | Lixte Biotechnology Holdings, Inc.: LIXTE Adds Northwestern University's Lurie Cancer Center as Second Site in Ongoing Clinical Trial for Ovarian Clear Cell Cancer | 1 | GlobeNewswire (USA) | ||
| 21.02. | LIXTE BIOTECHNOLOGY HOLDINGS, INC. - 8-K, Current Report | - | SEC Filings | ||
| 13.02. | Lixte Biotechnology Holdings, Inc.: LIXTE Biotechnology Announces Closing of $1.05 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules | 1 | GlobeNewswire (USA) | ||
| 13.02. | LIXTE BIOTECHNOLOGY HOLDINGS, INC. - 8-K, Current Report | - | SEC Filings | ||
| 11.02. | LIXTE Biotechnology announces $1.05M registered direct offering; shares fall | 3 | Seeking Alpha | ||
| 11.02. | Lixte Biotechnology Holdings, Inc.: LIXTE Biotechnology Announces $1.05 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules | 2 | GlobeNewswire (USA) | ||
| 10.02. | Lixte Biotechnology Holdings, Inc.: LIXTE Biotechnology Submits Request for Withdrawal of Form S-1 Registration Statement | 97 | GlobeNewswire (Europe) | PASADENA, CALIF., Feb. 10, 2025 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. ("LIXTE" or the "Company") (Nasdaq: LIXT and LIXTW), a clinical stage pharmaceutical company, today announced... ► Artikel lesen | |
| 06.01. | LIXTE BIOTECHNOLOGY HOLDINGS, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 27.12.24 | LIXTE BIOTECHNOLOGY HOLDINGS, INC. - 8-K, Current Report | - | SEC Filings | ||
| 20.12.24 | LIXTE BIOTECHNOLOGY HOLDINGS, INC. - 8-K, Current Report | - | SEC Filings | ||
| 02.12.24 | LIXTE BIOTECHNOLOGY HOLDINGS, INC. - 8-K, Current Report | - | SEC Filings | ||
| 01.11.24 | LIXTE BIOTECHNOLOGY HOLDINGS, INC. - S-1/A, General form for registration of securities | 1 | SEC Filings | ||
| 29.10.24 | Pre-market Movers: GlycoMimetics, BIO-key International, Lixte Biotechnology, Shuttle Pharmaceuticals, Profire Energy | 612 | AFX News | NORWALK (dpa-AFX) - The following are some of the stocks making big moves in Tuesday's pre-market trading (as of 08.30 A.M. ET).In the Green GlycoMimetics, Inc. (GLYC) is up over 163% at $0.4433.
BIO-key... ► Artikel lesen | |
| 23.10.24 | Lixte Biotechnology granted extension to meet Nasdaq listing rules | 3 | Investing.com | ||
| 23.10.24 | LIXTE BIOTECHNOLOGY HOLDINGS, INC. - 8-K, Current Report | 1 | SEC Filings |
Seite:
1 2 Weiter >>
30 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| INOVIO PHARMACEUTICALS | 1,430 | -5,92 % | INOVIO Pharmaceuticals, Inc.: INOVIO Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights | Significant progress toward submitting a biologics license application (BLA) for INO-3107 as a potential treatment for recurrent respiratory papillomatosis (RRP)... ► Artikel lesen | |
| OCUGEN | 0,590 | -7,24 % | Ocugen: Data and Safety Monitoring Board Reviews Cohort 1 Safety Data and Approves Dosing Cohort 2 in the Clinical Trial of OCU200-a Novel Fusion Protein for Diabetic Macular Edema | OCU200 has a very favorable safety and tolerability profileNo serious adverse events related to the study drug have been reportedDosing of the second cohort has been approved MALVERN, Pa., March 18... ► Artikel lesen | |
| MAINZ BIOMED | 5,695 | -100,00 % | EQS-News: Mainz BioMed N.V.: Mainz Biomed rekrutiert ersten Patienten für seine klinische eAArly DETECT 2-Studie | Emittent / Herausgeber: Mainz BioMed N.V.
/ Schlagwort(e): Studie
Mainz Biomed rekrutiert ersten Patienten für seine klinische eAArly DETECT 2-Studie
27.03.2025 / 14:01... ► Artikel lesen | |
| VIKING THERAPEUTICS | 21,690 | -8,44 % | Viking Therapeutics (NASDAQ:VKTX) Sets New 12-Month Low - Time to Sell? | ||
| IMMUNITYBIO | 2,646 | -5,74 % | Why ImmunityBio Inc. (IBRX) Went Up Last Week? | ||
| MARINOMED BIOTECH | 13,300 | 0,00 % | EQS-News: Marinomed Biotech AG: Marinomed nach erfolgreicher Sanierung mit Fokus auf Wachstum | EQS-News: Marinomed Biotech AG
/ Schlagwort(e): Sonstiges
Marinomed nach erfolgreicher Sanierung mit Fokus auf Wachstum
27.03.2025 / 07:45 CET/CEST
Für den Inhalt der... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 5,280 | 0,00 % | Why Biotech Stocks Like Recursion Pharmaceuticals, CRISPR Therapeutics, and Summit Therapeutics Plunged Today | ||
| ORAGENICS | 0,210 | 0,00 % | Oragenics, Inc. Provides Q1 2025 Shareholder Update on Strategic and Financial Progress | SARASOTA, Fla., March 27, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a biotechnology company focused on developing novel intranasal therapies for brain-related conditions, today... ► Artikel lesen | |
| FIBROGEN | 0,287 | +0,95 % | FibroGen, Inc.: FibroGen Announces Publication of Results from Phase 1 Monotherapy Study of FG-3246 in Patients with Metastatic Castration-Resistant Prostate Cancer in the Journal of Clinical Oncology | FG-3246 showed encouraging anti-cancer activity with an acceptable safety profile in patients with metastatic castration-resistant prostate cancerInitiation of Phase 2 monotherapy dose optimization... ► Artikel lesen | |
| REVIVE THERAPEUTICS | 0,001 | -94,12 % | Revive Therapeutics Ltd.: Revive Therapeutics Announces Acquisition of Molecular Hydrogen Program | TORONTO, April 01, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. ("Revive" or the "Company") (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research... ► Artikel lesen | |
| CAPRICOR | 8,790 | -2,01 % | Capricor Therapeutics to Present at the 2025 Piper Sandler Virtual Cardio Day | ||
| BIOLINERX | 3,283 | -100,00 % | BioLineRx Ltd.: BioLineRx Reports 2024 Financial Results and Provides Corporate Update | - Reports meaningful progress in the evaluation of assets for potential in-licensing and development in the areas of oncology and rare diseases -
- Executed license... ► Artikel lesen | |
| RADIUS HEALTH | - | - | +850% CVR-Jackpot: Biotech-Tipp Radius Health beschert Anlegern Geldsegen | Der Optionsvoodoo-Chatraum von sharedealsPlus brummte letzte Woche vor Begeisterung, denn ein längst vergessener Trade sorgt für Jubelstürme und prall gefüllte Konten bei den Mitgliedern des Anlegerclubs... ► Artikel lesen | |
| MARKER THERAPEUTICS | 0,945 | -5,50 % | Marker Therapeutics Reports Year-End 2024 Corporate and Financial Results | Lead program investigating MT-601 in patients with refractory lymphomas, including anti-CD19 CAR-T cell therapy, demonstrated safety and efficacy in 9 patients with 78% having objective responses... ► Artikel lesen | |
| CAN-FITE BIOPHARMA | 1,480 | 0,00 % | RedChip Companies, Inc.: bioAffinity Technologies and Can-Fite BioPharma Interviews to Air on the RedChip Small Stocks, Big Money Show on Bloomberg TV | ORLANDO, FLORIDA / ACCESS Newswire / March 28, 2025 / RedChip Companies will air interviews with bioAffinity Technologies, Inc. (Nasdaq:BIAF) and Can-Fite BioPharma Ltd. (NYSE American:CANF) on the... ► Artikel lesen |
Das Unternehmen LIXTE BIOTECHNOLOGY HOLDINGS INC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 1,250 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu LIXTE BIOTECHNOLOGY HOLDINGS INC finden Sie auf Wallstreet Online.
